EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity

Olufemi Aoko iD, Tobias Maharaj iD, Fiona Boland iD, Danny Cheriyan iD, John Ryan iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17805 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Olufemi Aoko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Department, Beaumont Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Gastric Balloon, Bariatric Surgery. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beaumont Hospital Dublin, Charitable Infirmary Charitable Trust - Kieran Taaffe Bursary, Royal College of Surgeons in Ireland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy ‐a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.

Aim

To evaluate the effect of IGB as a treatment option in NAFLD.

Methods

We searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver‐related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non‐comparative studies; primary outcomes were liver‐related NAFLD surrogates.

Results

We included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): −3.0 [95% CI: −2.41 to −3.59], ALT: MD: −10.40 U/L [95% CI: −7.31 to −13.49], liver volume: MD ‐397.9 [95% CI: −212.78 to 1008.58] and liver steatosis: MD: −37.76 dB/m [95% CI: −21.59 to −53.92]. There were significant reductions in non‐liver‐related outcomes of body weight, BMI, glycated haemoglobin and HOMA‐IR.

Conclusion

Intragastric balloons may play an important role in addressing the treatment gap in NAFLD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseGastric BalloonBariatric SurgeryAdultHumansObesity

Stichwörter der Autor:innen

Intragastric balloonbariatric endoscopyendoscopic bariatric therapiesinsulin resistancenon-alcoholic fatty liver diseaseobesity

Autor:innen und Institutionen

  • Hepatology Department, Beaumont Hospital, Dublin, Ireland.
  • Gastroenterology Department, Beaumont Hospital, Dublin, Ireland.
  • Royal College of Surgeons Ireland, Dublin, Ireland.

ORCID-Profile: Olufemi Aoko, Tobias Maharaj, Fiona Boland, Danny Cheriyan, John Ryan

Förderung

  • Beaumont Hospital Dublin
  • Charitable Infirmary Charitable Trust - Kieran Taaffe Bursary
  • Royal College of Surgeons in Ireland

Zitieren

APA

Aoko, O., Maharaj, T., Boland, F., Cheriyan, D., & Ryan, J. (2024). Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17805

Vancouver

Aoko O, Maharaj T, Boland F, Cheriyan D, Ryan J. Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17805

BibTeX
@article{Aoko2024,
  author = {Aoko, Olufemi and Maharaj, Tobias and Boland, Fiona and Cheriyan, Danny and Ryan, John},
  title = {Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17805}
}
Kostenlos starten →